Drugmaker Sanofi expects further profit growth from narrowed focus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Regeneron (REGN) Reports Positive 2-Yr Results from Phase 3 PANORAMA Trial Evaluating EYLEA (aflibercept) Injection 2mg
February 10, 2020 6:15 AM ESTRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced positive two-year results from the Phase 3 PANORAMA trial evaluating EYLEA® (aflibercept) Injection 2 mg (0.05 mL) in patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR). The data were presented today for the first time at the Angiogenesis, Exudation, and Degeneration 2020 meeting in Miami, Florida.
The two-year pre-specified exploratory data demonstrate that untreated moderately severe and... More
Sanofi (SNY) Reports Q4 Revenues of EUR9.61B
February 6, 2020 8:05 AM ESTSanofi (NASDAQ: SNY) reported Q4 EPS of EUR1.34. Revenue for the quarter came in at EUR9.61 billion.
Sanofi Chief Executive Officer, Paul Hudson, commented:
"I am encouraged by the fourth quarter results which position Sanofi to deliver on our new strategic priorities.... More
